Equities analysts expect Merus NV (NASDAQ:MRUS) to post earnings per share of ($0.60) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Merus’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.63). Merus posted earnings of ($0.57) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 5.3%. The firm is expected to report its next quarterly earnings results on Monday, August 17th.
According to Zacks, analysts expect that Merus will report full year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($2.54) to ($2.04). For the next year, analysts expect that the company will report earnings of ($2.47) per share, with EPS estimates ranging from ($2.91) to ($1.96). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Merus.
Merus (NASDAQ:MRUS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%. The company had revenue of $6.30 million during the quarter, compared to analyst estimates of $8.05 million.
Shares of NASDAQ:MRUS traded up $0.23 during trading on Wednesday, hitting $15.28. 1,669 shares of the company were exchanged, compared to its average volume of 205,859. Merus has a fifty-two week low of $10.19 and a fifty-two week high of $20.95. The stock has a market cap of $437.05 million, a price-to-earnings ratio of -5.74 and a beta of 0.75. The firm has a fifty day moving average price of $15.18 and a two-hundred day moving average price of $15.33.
In other Merus news, major shareholder Bvf Partners L. P/Il purchased 1,462,510 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $14.00 per share, with a total value of $20,475,140.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bvf Partners L. P/Il acquired 87,254 shares of the company’s stock in a transaction on Monday, June 8th. The stock was acquired at an average price of $15.20 per share, with a total value of $1,326,260.80. The disclosure for this purchase can be found here. 7.40% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in MRUS. UBS Group AG bought a new position in shares of Merus during the fourth quarter worth approximately $30,000. Marshall Wace North America L.P. acquired a new stake in Merus during the fourth quarter worth approximately $34,000. Global Retirement Partners LLC increased its stake in Merus by 62.7% during the 1st quarter. Global Retirement Partners LLC now owns 2,603 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 1,003 shares during the period. California Public Employees Retirement System increased its stake in Merus by 14.4% during the 4th quarter. California Public Employees Retirement System now owns 11,441 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 1,441 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in Merus by 29.5% in the 4th quarter. Acadian Asset Management LLC now owns 12,035 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,740 shares in the last quarter. Hedge funds and other institutional investors own 62.02% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Further Reading: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.